Addressing Critical Unmet Needs in ES-SCLC Patient Management
Panelists discuss how major unmet needs in extensive-stage small cell lung cancer—such as lack of durable responses, limited second-line options, absence of predictive biomarkers, and challenges managing brain metastases—underscore the urgency for more effective therapies and comprehensive supportive care strategies.
EP: 1.ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management
EP: 4.Clinical Trials: Novel Approaches in Second-Line ES-SCLC
Summary for Physicians:
Several unmet needs remain in the treatment of extensive-stage small cell lung cancer (ES-SCLC) despite recent advancements.
Key challenges include the following:
- Lack of durable responses: Although initial response rates to chemotherapy and immunotherapy are high, most patients experience rapid disease progression, highlighting the need for treatments that provide longer-term control.
- Limited options in the relapsed setting: There are few effective therapies after first-line treatment failure, with modest efficacy from currently available second-line agents.
- Absence of predictive biomarkers: There is a pressing need for biomarkers that can guide treatment selection and identify patients most likely to benefit from specific therapies, including immunotherapy.
- Management of brain metastases: Central nervous system involvement is common in ES-SCLC, and effective strategies for prevention and treatment are still lacking.
- Supportive care needs: The aggressive nature of the disease and rapid decline in performance status emphasize the importance of early palliative care integration and better management of symptoms and treatment-related toxicity.
Addressing these gaps is crucial to improving outcomes and quality of life for patients with ES-SCLC.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
